Spain

Short-Term Outlook: 2010

Reinforcing BMI's view that companies with significant exposure to European markets will be hard hit by government austerity measures across the region, and in particular by pharmaceutical... 2010-05-27

BMI Core View: The introduction of government price erosion mechanisms will accelerate across Europe, driven by the need for fiscal austerity and presaged by the actions of numerous... 2010-05-14

BMI Core View: The uptake of generic drugs following patent expiries will become swifter, reducing costs for governments, out-of-pocket payers and insurance companies - increasingly... 2010-05-11

With the aim of slashing EUR1.5bn (US$2.0bn) from its annual drugs bill, the Spanish government has implemented a new reference pricing system that includes price cuts of up to 25%... 2010-05-10

As established under the reforms to Spain's Medicines Law in 2006, reimbursed medicines with the same active ingredient and mode of administration, and which have at least one generic... 2010-01-20

The Spanish pharmaceuticals market is among the top five in Europe and the top 10 in the world by value. It has grown strongly in recent years, outperforming the majority of others... 2009-12-14